Clinical Trial Update: Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase

View source ↗

Summary

This clinical trial update reports on front-line nilotinib treatment for patients with chronic phase BCR-ABL positive chronic myeloid leukemia (CML-CP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Chronic Phase Philadelphia Positive, BCR-ABL Positive | Status: COMPLETED